MOVALIS Tablets

PRODUCT INFORMATION

NAME OF THE MEDICINE

Approved Name: Meloxicam

Chemical Names: 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H,1,2-benzothiazine-3-carboxamide-1,1-dioxide

2H,1,2-benzothiazine-3-carboxamide,4-hydroxy-2-methyl-N(5-methyl-2-thiazolyl)-1,1-dioxide

The molecular formula of meloxicam is C\textsubscript{14}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S\textsubscript{2}, the molecular weight is 351.4, and the CAS number is 71125-38-7. The structural formula of meloxicam is as follows:

![Structural formula of meloxicam]

DESCRIPTION

Meloxicam is a pastel yellow solid with pKa values of 1.09 and 4.18 and a melting point of about 256°C. The substance is practically insoluble in water, soluble in dimethylformamide, slightly soluble in chloroform and acetone, and very slightly soluble in methanol. There are no chiral centres and no polymorphs are formed under normal conditions.

MOVALIS is available as tablets containing 7.5 mg and 15 mg of meloxicam. The excipients are sodium citrate, lactose, microcrystalline cellulose, povidone, crospovidone, colloidal anhydrous silica, magnesium stearate.

PHARMACOLOGY

MOVALIS is a non-steroidal anti-inflammatory drug (NSAID) of the enolic acid class, which has shown anti-inflammatory, analgesic and antipyretic properties in animals. Meloxicam showed anti-inflammatory activity in all standard models of inflammation. A common mechanism for the above effects may exist in the ability of meloxicam to inhibit the biosynthesis of prostaglandins, known mediators of inflammation, by inhibition of cyclooxygenase (COX).
Comparison of the ulcerogenic dose and the anti-inflammatory effective dose in rat adjuvant arthritis confirmed a greater therapeutic margin in animals over other NSAIDs (piroxicam, diclofenac, naproxen, flurbiprofen). In rats, meloxicam showed greater inhibitory effect on prostaglandin biosynthesis at the site of inflammation than in the gastric mucosa or the kidney.

Selective inhibition of the cyclooxygenase-2 (COX-2) isoenzyme, relative to COX-1, by meloxicam has been demonstrated in vitro on various cell systems: guinea pig macrophages, bovine aortic endothelial cells (for testing of COX-1 activity), mouse macrophages (for testing for COX-2 activity), and human recombinant enzymes expressed in cos-cells and in human whole blood.

**Pharmacokinetics**

**Absorption**

Meloxicam is well absorbed following oral administration (absolute bioavailability 89%). Once daily dosing leads to drug plasma concentrations with a relatively small peak-trough fluctuation in the range of 0.4-1.0 µg/mL for 7.5 mg doses or 0.8-2.0 µg/mL for 15 mg doses. However, values outside of this range have been encountered (C_{min} and C_{max} at steady state, respectively). The absorption is not altered by concomitant food intake. Maximum plasma concentrations were regularly achieved between 5-6 hours following tablet administration, irrespective of concomitant food consumption. Drug concentrations are dose-proportional for oral 7.5 mg and 15 mg doses, respectively. Steady state conditions are achieved in three to five days. Continuous treatment for periods of up to six months results in similar drug concentrations to those seen once steady state is first achieved.

**Distribution**

Volume of distribution is low (on average, 11L). In plasma, more than 99% is bound to plasma proteins. Meloxicam penetrates well into synovial fluid to give concentrations approximately half those in plasma.

**Metabolism**

Meloxicam is eliminated almost entirely by hepatic metabolism: two thirds by cytochrome (CYP) P450 enzymes (CYP 2C9 two thirds and CYP 3A4 one third) and one third by other pathways, such as peroxidase oxidation. Meloxicam is almost completely metabolised to four pharmacologically inactive metabolites. The major metabolite, 5'-carboxymeroxicam (60% of dose), from CYP 2C9 mediated metabolism, is formed by oxidation of an intermediate metabolite 5'-hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP 2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP 3A4 isoenzyme. The patient’s peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose respectively.

**Elimination**

Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the faeces and urine. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and faeces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.

There is significant biliary and/or enteral secretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%. Meloxicam is eliminated from the body with a mean elimination half-life of 20 hours. Plasma clearance ranges from 7-9 mL/min.
**Hepatic impairment**
Following a single 15 mg dose of meloxicam, there was no marked difference in plasma concentrations in subjects with mild (Child-Pugh Class I) and moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein binding of meloxicam was not affected by hepatic insufficiency. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied.

**Renal impairment**
Meloxicam pharmacokinetics have been investigated in subjects with different degrees of renal insufficiency. Total drug plasma concentrations decreased with the degree of renal impairment, while free AUC values were similar. Total clearance of meloxicam increased in these patients, probably due to the increase in free fraction, leading to an increased metabolic clearance. There is no need for dose adjustment in patients with mild to moderate renal failure (creatinine clearance greater than 25 mL/min). Patients with severe renal insufficiency have not been adequately studied. The use of MOVALIS in patients with severe renal impairment is not recommended.

**Hemodialysis**
Following a single dose of meloxicam, the free \( C_{\text{max}} \) plasma concentrations were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialysable.

**Elderly**
Clearance is decreased in the elderly. In clinical studies, steady state pharmacokinetics in the elderly (mean age 67) did not differ significantly from those in a younger population (mean age 50), however elderly females had a higher systemic exposure to meloxicam than did elderly males.

**Gender**
Young females exhibited slightly lower plasma concentrations relative to young males. After single doses of 7.5 mg MOVALIS, the mean elimination half life was 19.5 hours for the female group as compared to 23.4 hours for the male group. At steady state, the data were similar (17.9 hours vs. 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the \( C_{\text{max}} \) or \( t_{\text{max}} \) across genders.

**CLINICAL TRIALS**
The efficacy of meloxicam in treating the symptoms of osteoarthritis has been confirmed in several clinical studies. Two clinical studies of 6 months duration were performed in patients with osteoarthritis of the hip or knee. In the first study, the efficacy of meloxicam 15 mg (n=306) and piroxicam 20 mg (n=149) were found to be comparable, using as efficacy endpoints improvement in overall pain, pain on movement, global efficacy, change in duration of inactivity and change in quality of life score. In the second study, the efficacy of meloxicam 7.5 mg (n=169) was found to be comparable to that of diclofenac 100 mg SR (n=167) using similar endpoints.

Once daily dosing of meloxicam 7.5 mg (n=153) and 15 mg (n=156) showed a consistently more efficacious response than placebo (n=155) in a 12 week trial in patients with osteoarthritis of the knee or hip. Efficacy was measured by global assessment of disease activity, global assessment of pain and arthritic condition, as measured by the WOMAC (Western Ontario and McMaster University) Osteoarthritis Index. Both doses of meloxicam were also shown to be comparable to diclofenac 50 mg BID (n=152) with regard to efficacy, with a lower incidence of GI adverse events when compared to diclofenac.
Two large scale, randomised, active-controlled clinical studies of 4 weeks duration were conducted in patients with osteoarthritis of the hand, hip, knee or spine. In the first study (MELISSA), the effects of meloxicam 7.5 mg (n=4635) were compared against the effects of diclofenac 100 mg SR (n=4688). In the second study (SELECT), the effects of meloxicam 7.5 mg (n=4320) were compared against the effects of piroxicam 20 mg (n=4336). The results from both studies indicated that meloxicam 7.5 mg was as efficacious as diclofenac 100 mg SR and piroxicam 20 mg, in the treatment of symptomatic osteoarthritis.

INDICATIONS

MOVALIS is indicated for the symptomatic treatment of osteoarthritis.

CONTRAINDICATIONS

- Peri-operative treatment of pain in patients undergoing coronary artery bypass graft surgery (CABG)
- Known hypersensitivity to meloxicam or any excipients of the product. There is a potential for cross sensitivity to aspirin and other NSAIDs.
- Signs/symptoms of asthma, nasal polyps, angioedema or urticaria, following the administration of aspirin or other NSAIDs.
- Active gastrointestinal ulceration/perforation
- Active inflammatory Bowel Disease (Crohn’s Disease or Ulcerative Colitis)
- Severe hepatic insufficiency
- Non-dialysed severe renal insufficiency
- Severe uncontrolled heart failure
- Children and adolescents under 18 years of age
- Breastfeeding
- Concomitant administration of drugs known to inhibit CYP 2C9 (eg. sulfaphenazole, sulfipyrazone, sulfamethoxazole and fluconazole)
- The use of MOVALIS tablets is contraindicated in patients with rare hereditary galactose intolerance, due to the lactose content of the formulations.

As with all NSAIDs, MOVALIS is contraindicated in patients with recent cerebrovascular bleeding or established systemic bleeding disorders.

PRECAUTIONS

Gastrointestinal effects
As with other NSAIDs gastrointestinal (GI) bleeding, ulceration or perforation, potentially fatal, can occur at any time during treatment, with or without warning symptoms, or a previous history of serious GI events. The consequences of such events are generally more serious in the elderly. Minor upper GI problems, such as dyspepsia, are common and may occur at any time during NSAID therapy. Therefore physicians and patients should remain alert for ulceration and bleeding, even in the absence of previous GI tract symptoms. Patients should be informed about the signs and/or symptoms of serious GI toxicity and the steps to take if they occur. The utility of periodic laboratory monitoring has not been demonstrated, nor has it been adequately assessed. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. It has been demonstrated that upper GI ulcers, gross bleeding or perforation, caused by NSAIDs, appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These
trends continue, increasing the likelihood of developing a serious adverse GI event at some time during the course of therapy. However, even short term therapy is not without risk.

Studies have shown that patients with a prior history of ulcer disease and/or GI bleeding and who use NSAIDs have a greater than 10 fold higher risk of developing a GI bleed than patients with neither of these factors.

Caution is advised in patients most at risk of developing a GI complication with NSAIDs: the elderly, patients using any other NSAID or aspirin concomitantly or patients with a prior history of or recent GI disease such as ulceration and GI bleeding.

NSAIDs should be prescribed with caution in patients with a prior history of recent ulcer disease or GI bleeding.

For high risk patients, alternate therapies that do not involve NSAIDs should be considered.

In clinical trials, meloxicam has been shown to cause fewer GI adverse events (including dyspepsia, abdominal pain, nausea, vomiting etc.) than other NSAIDs with which it has been compared (see Table 1).

Table 1: Incidence of GI adverse events (%) after 4 weeks, 12 weeks and 6 months

<table>
<thead>
<tr>
<th>4 week treatment</th>
<th>12 week treatment</th>
<th>6 month treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELISSA/SELECT</td>
<td>placebo-controlled trial</td>
<td>active-controlled trials</td>
</tr>
<tr>
<td>melox. 7.5 mg</td>
<td>diclo. (SR) 100 mg</td>
<td>pirox. 20 mg</td>
</tr>
<tr>
<td>n=8955</td>
<td>n=4688</td>
<td>n=4336</td>
</tr>
<tr>
<td>12%</td>
<td>19%</td>
<td>15%</td>
</tr>
</tbody>
</table>

**KEY:** melox. = meloxicam; pirox. = piroxicam; diclo. = diclofenac; SR = slow release; BID = twice daily

Caution should be exercised when treating patients with a history of upper gastrointestinal disease and in patients receiving treatment with anticoagulants. Patients with GI symptoms should be monitored. MOVALIS therapy should cease if peptic ulceration or GI ulceration or bleeding occurs.

Co-administration of meloxicam with drugs known to inhibit CYP 3A4 should be undertaken with caution. A combination of meloxicam and substances known to inhibit both CYP 3A4 and CYP 2C9 should be avoided because of the increased risk of toxicity.

**Cardiovascular effects**
Long term therapy with some COX-2 selective NSAIDs of the coxib class has been shown to increase the risk of serious cardiovascular thrombotic events. MOVALIS is a COX-2 selective NSAID. MOVALIS has not been demonstrated to increase the risk of cardiovascular adverse events compared to nonselective NSAIDs in clinical trials. However, long term placebo controlled data to adequately assess any cardiovascular risk are not available for MOVALIS.

All NSAIDs, both COX-2 selective and nonselective, may cause an increased risk of serious cardiovascular thrombotic events. This may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

MOVALIS should be used at the lowest dose and for the shortest duration consistent with effective treatment.
Skin reactions
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of MOVALIS. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. MOVALIS should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Renal effects
NSAIDs inhibit the synthesis of renal prostaglandins, which play a supportive role in the maintenance of renal perfusion. In patients whose renal blood flow and blood volume are decreased, administration of an NSAID may precipitate overt renal decompensation which is typically followed by recovery to pretreatment state upon discontinuation of nonsteroidal anti-inflammatory therapy.

Patients at greatest risk of such a reaction are elderly individuals, dehydrated patients, those with congestive heart failure, liver cirrhosis, nephrotic syndrome and overt renal disease, those receiving concomitant treatment with a diuretic, ACE inhibitor or angiotensin II receptor antagonist or those having undergone major surgical procedures which led to hypovolaemia. In such patients, the renal function, including volume of diuresis, should be carefully monitored at the beginning of therapy.

In rare cases, NSAIDs may cause interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome.

The dose of MOVALIS in patients with end-stage renal failure on haemodialysis should not be higher than 7.5 mg. No dose reduction is required in patients with mild or moderate renal impairment (i.e., in patients with a creatinine clearance of greater than 20 mL/min).

The extent to which metabolites of meloxicam may accumulate in patients with renal failure has not been studied. As some metabolites are excreted by the kidney, patients with significantly impaired renal function should be more closely monitored.

Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diuretics
The use of an ACE inhibiting drug (ACE-inhibitor or angiotensin receptor antagonist), an antiinflammatory drug (NSAID or COX-2 inhibitor) and a thiazide diuretic at the same time increases the risk of renal impairment. This includes use in fixed-combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the combination. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment.

Hepatic effects
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including MOVALIS. These laboratory values may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, have been reported with NSAIDs.

Patients with signs and/or symptoms suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with MOVALIS. If clinical signs and symptoms consistent with liver disease
develop, or if systemic manifestations occur (eg. eosinophilia, rash, etc), MOVALIS should be discontinued.

**Fluid retention and oedema**
Induction of sodium, potassium and water retention and interference with the natriuretic effects of diuretics may occur with NSAIDs. Cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. For patients at risk, clinical monitoring is recommended.

**Driving and operating machinery**
There are no specific studies about effects on the ability to drive vehicles and to use machinery. Patients who experience visual disturbances, drowsiness or other central nervous system disturbances should refrain from these activities.

**Pre-existing asthma**
Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, MOVALIS should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing asthma.

**Use in patients being treated with corticosteroids**
MOVALIS cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

**Use in patients with fever and infection**
The pharmacological activity of MOVALIS in reducing inflammation and possibly fever may diminish the utility of these diagnostic signs in detecting complications of presumed non-infectious, painful conditions.

**Anaphylactoid reactions**
As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to meloxicam. MOVALIS should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. Emergency help should be sought in cases where an anaphylactoid reaction occurs.

**Lactose**
MOVALIS tablets 7.5 mg contain 47 mg lactose and MOVALIS tablets 15 mg contain 20 mg lactose per maximum recommended daily dose. Patients with rare hereditary conditions of galactose intolerance, eg galactosaemia should not take this medicine.

**Effects on fertility**
Oral treatment with meloxicam at doses up to 5 mg/kg/day in female rats (approximately 2.7 times the human dose based on BSA) and up to 9 mg/kg/day (approximately 5 times the human dose based on BSA) in male rats did not affect mating behaviour or fertility.

Oral treatment of female rats with meloxicam at doses of 1 mg/kg/day (approximately half of the human dose based on BSA) reduced the number of embryonic implantations and increased the number of early resorptions. A no-effect dose for these effects was not established. A reduction in the number of corpora lutea was also observed at 5 mg/kg/day, with the no-effect dose being 2.5 mg/kg/day (approximately 1.5 fold greater than the human dose based on BSA).
The use of meloxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. Meloxicam may delay ovulation. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered.

**Use in Pregnancy (Category C)**

Meloxicam use is not recommended in pregnancy unless it is considered clinically essential.

NSAIDs inhibit prostaglandin synthesis and, when given during the latter part of pregnancy, may cause closure of the fetal ductus arteriosus, fetal renal impairment, inhibition of platelet aggregation and delay of labour and birth. Continuous treatment with NSAIDs during the last trimester of pregnancy should only be given on sound indications. During the last few days before expected birth, agents with inhibitory effects on prostaglandin synthesis should be avoided.

Meloxicam was not teratogenic in rats up to an oral dose of 4 mg/kg/day (approximately 2.2 times the human dose at 15 mg/day for a 50 kg adult based on body-surface-area [BSA]) when given during organogenesis. Meloxicam caused an increased incidence of septal defect of the heart, a rare event, at an oral dose of 60 mg/kg/day (about 60 times the human dose based on BSA) and embryolethality at oral doses ≥ 5 mg/kg/day (5 times the human dose based on BSA) when rabbits were treated throughout organogenesis.

Studies in rats with meloxicam, as with other drugs known to inhibit prostaglandin synthesis, showed an increased incidence of still births, increased length of delivery time and delayed parturition at oral doses > 1 mg/kg/day (approximately 0.6 times the human dose based on BSA), and decreased pup survival at an oral dose of 4 mg/kg/day (approximately 2.1 times the human dose based on BSA) throughout organogenesis. Similar findings were observed in rats receiving oral doses > 0.125 mg/kg/day (less than 0.1 times the human dose based on BSA) during late gestation and the lactation period.

Meloxicam crosses the placental barrier. There are no adequate, well-controlled studies in pregnant women. Meloxicam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Use in Lactation**

Studies of meloxicam excretion in human milk have not been conducted. However, meloxicam was excreted in the milk of lactating rats at concentrations higher than those in plasma. The safety of meloxicam in humans during lactation has not been established and therefore, the drug should not be used during lactation.

**Paediatric Use**

MOVALIS is not recommended for use in children and adolescents under 18 years of age (see CONTRAINDICATIONS).

**Use in the Elderly**

Frail or debilitated patients may tolerate side effects less well and such patients should be carefully supervised. As with other NSAIDs, caution should be used in the treatment of elderly patients who are more likely to be suffering from impaired renal, hepatic, or cardiac function.

**Genotoxicity**

Meloxicam did not demonstrate genotoxic potential in assays for gene mutation *in vitro* and chromosomal damage *in vitro* and *in vivo*. 
Carcinogenicity
Two year dietary studies showed no evidence for carcinogenic activity at meloxicam doses up to 0.8 mg/kg/day (approximately half of the highest human dose at 15 mg/day for a 50 kg person based on body-surface-area [BSA]) in rats and up to 8 mg/kg/day (2.2 times the highest human dose based on BSA) in mice. In rats, the highest dose used was nephrotoxic, while the highest dose used in mice was subtoxic.

INTERACTIONS WITH OTHER MEDICINES

General
In vitro drug interaction studies revealed that the metabolism of meloxicam is predominantly mediated via the CYP 2C9 isoenzyme, with a minor contribution of the CYP 3A4 isoenzyme in the liver. Co-administration of meloxicam with drugs known to inhibit CYP 2C9 is contraindicated. Co-administration of meloxicam with drugs known to inhibit CYP 3A4 (ketoconazole, itraconazole, erythromycin) or drugs known to be metabolised by CYP 3A4 (terfenadine, astemizole, cyclosporin, class III antiarythmic drugs such as amiodarone and quinidine) should be undertaken with caution (see PRECAUTIONS - Gastrointestinal effects).

Antacids
No pharmacokinetic interaction was detected with concomitant administration of antacids.

Cimetidine
Concomitant administration of 200 mg cimetidine QID did not alter the single dose pharmacokinetics of 30 mg meloxicam.

Digoxin
Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after beta-acetyldigoxin administration for 7 days at clinical doses. In vitro testing found no protein binding drug interaction between digoxin and meloxicam.

Frusemide
Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of frusemide and thiazide diuretics in some patients. This effect has been attributed to inhibition of renal prostaglandin synthesis. Studies with frusemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Frusemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. Nevertheless, during concomitant therapy with frusemide and meloxicam, patients should be observed closely for signs of declining renal function (see INTERACTIONS WITH OTHER MEDICINES, Diuretics), as well as to assure diuretic efficacy.

Other Prostaglandin Synthetase Inhibitors (PSIs), including glucocorticoids and salicylates (acetylsalicylic acid)
Co-administration of PSIs may increase the risk of gastrointestinal ulcers bleeding, via a synergistic effect, and it is not recommended. The concomitant use of meloxicam with other NSAIDs is not recommended.

Oral anticoagulants, antiplatelet drugs, systemically administered heparin, thrombolytics and Selective Serotonin Reuptake Inhibitors (SSRIs)
There is an increased risk of bleeding via inhibition of platelet function, when NSAIDs are co-administered. If such co-prescribing cannot be avoided, close monitoring of their effect on coagulation is required.
Oral anticoagulants, systemically administered heparin, thrombolytics and ticlopidine
There is an increased risk of bleeding when NSAIDs are co-administered. If such co-prescription cannot be avoided, close monitoring of the effects of anticoagulants is required.

Lithium
NSAIDs have been reported to increase lithium plasma levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended. If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of meloxicam treatment.

Methotrexate
Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. In vitro, methotrexate did not displace meloxicam from human serum binding sites. However, as with other NSAIDs, MOVALIS may increase the haematologic toxicity of methotrexate. In this situation, strict monitoring of blood cell count is recommended.

NSAIDs can reduce the tubular secretion of methotrexate thereby increasing the plasma concentrations of methotrexate. For this reason, for patients on high dosages of methotrexate (more than 15 mg/week) the concomitant use of NSAIDs is not recommended. The risk of an interaction between NSAIDs and methotrexate should be considered also in patients on low dosage of methotrexate, especially in patients with impaired renal function. In case combination treatment is necessary, blood cell count and renal function should be monitored. Caution should be taken in case both NSAID and methotrexate are given within 3 days, in which case the plasma level of methotrexate may increase and cause increased toxicity. Although the pharmacokinetics of methotrexate (15 mg/week) were not affected by concomitant meloxicam treatment, it should be considered that the haematological toxicity of methotrexate can be amplified by treatment with NSAIDs.

Pemetrexed
For the concomitant use of meloxicam with pemetrexed in patients with creatinine clearance from 45 to 79 mL/min, the administration of meloxicam should be paused for 5 days before, on the day of, and 2 days following pemetrexed administration. If a combination of meloxicam with pemetrexed is necessary, patients should be closely monitored, especially for myelosuppression and gastro-intestinal adverse reactions. In patients with creatinine clearance below 45 mL/min the concomitant administration of meloxicam with pemetrexed is not recommended.

Contraception
NSAIDs have been reported to decrease the efficacy of intrauterine devices.

Diuretics
Treatment with NSAIDs is associated with the potential for acute renal insufficiency in patients who are dehydrated. Patients receiving MOVALIS and diuretics should be adequately hydrated and be monitored for renal function prior to initiating treatment.

Cyclosporin
Nephrotoxicity of cyclosporin may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combined treatment, renal function is to be measured.

Antihypertensives (beta-blockers, certain ACE-inhibitors, vasodilators, diuretics)
A reduced effect of the antihypertensive drug by inhibition of vasodilating prostaglandins has been reported during treatment with NSAIDs.
Angiotensin-II receptor antagonists
NSAIDs and angiotensin-II receptor antagonists as well as ACE inhibitors exert a synergistic effect on the decrease of glomerular filtration. In patients with pre-existing renal impairment this may lead to acute renal failure.

Cholestyramine
Cholestyramine binds to meloxicam in the gastrointestinal tract leading to a faster elimination of meloxicam.

Oral hypoglycaemics
Interactions with oral hypoglycaemics cannot be excluded.

ADVERSE REACTIONS

The MOVALIS phase II/III safety database includes 10,122 patients treated with MOVALIS 7.5 mg/day and 3,505 patients treated with MOVALIS 15 mg/day. MOVALIS at these doses was administered to 661 patients for at least six months and to 312 patients for at least one year. Approximately 10,500 of these patients were treated in ten placebo and or active-controlled osteoarthritis trials. Gastrointestinal (GI) adverse events were the most frequently reported adverse events in all treatment groups across MOVALIS trials.

A 12-week, multicentre, double-blind, randomised trial was conducted in patients with osteoarthritis of the knee or hip to compare the efficacy and safety of MOVALIS with placebo and with an active control. Table 2 presents the adverse events that occurred in ≥ 1% of the MOVALIS treatment groups.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>MOVALIS 7.5 mg daily</th>
<th>MOVALIS 15 mg daily</th>
<th>diclofenac 100 mg daily</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of patients</strong></td>
<td>157</td>
<td>154</td>
<td>156</td>
<td>153</td>
</tr>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear disorder</td>
<td>0</td>
<td>0</td>
<td>1.3</td>
<td>0.7</td>
</tr>
<tr>
<td>Vertigo</td>
<td>0</td>
<td>0.6</td>
<td>1.3</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataract</td>
<td>0</td>
<td>0</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2.5</td>
<td>1.9</td>
<td>2.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Constipation</td>
<td>1.9</td>
<td>1.9</td>
<td>0.6</td>
<td>3.9</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>3.8</td>
<td>7.8</td>
<td>3.2</td>
<td>9.2</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>4.5</td>
<td>4.5</td>
<td>4.5</td>
<td>6.5</td>
</tr>
<tr>
<td>Eruetion</td>
<td>0</td>
<td>0</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td>Flatulence</td>
<td>4.5</td>
<td>3.2</td>
<td>3.2</td>
<td>3.9</td>
</tr>
<tr>
<td>Gastro-oesophageal reflux disease</td>
<td>0.6</td>
<td>1.9</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Nausea</td>
<td>3.2</td>
<td>3.9</td>
<td>3.8</td>
<td>7.2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.9</td>
<td>1.3</td>
<td>1.3</td>
<td>2.6</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.9</td>
<td>1.9</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Gravitational oedema</td>
<td>0.6</td>
<td>1.3</td>
<td>1.9</td>
<td>3.3</td>
</tr>
<tr>
<td>Influenza like illness</td>
<td>5.1</td>
<td>4.5</td>
<td>5.8</td>
<td>2.6</td>
</tr>
<tr>
<td>Oedema peripheral</td>
<td>1.3</td>
<td>0.6</td>
<td>3.2</td>
<td>0</td>
</tr>
<tr>
<td>Medical Conditions</td>
<td>Placebo</td>
<td>MOVALIS 7.5 mg daily</td>
<td>MOVALIS 15 mg daily</td>
<td>diclofenac 100 mg daily</td>
</tr>
<tr>
<td>---------------------------------------------------------</td>
<td>---------</td>
<td>----------------------</td>
<td>---------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>1.9</td>
<td>1.9</td>
<td>0.6</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>1.3</td>
<td>0.6</td>
<td>3.2</td>
<td>1.3</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>5.1</td>
<td>1.3</td>
<td>1.9</td>
<td>5.9</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>1.9</td>
<td>3.2</td>
<td>1.9</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>Injury, poisoning and procedural complications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accident at home</td>
<td>1.9</td>
<td>4.5</td>
<td>3.2</td>
<td>2.6</td>
</tr>
<tr>
<td>Fall</td>
<td>0.6</td>
<td>2.6</td>
<td>0</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td>0</td>
<td>1.3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Increased appetite</td>
<td>0.6</td>
<td>0</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1.9</td>
<td>1.9</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Arthritis</td>
<td>0</td>
<td>0</td>
<td>1.9</td>
<td>0</td>
</tr>
<tr>
<td>Back pain</td>
<td>3.2</td>
<td>1.3</td>
<td>1.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Bursitis</td>
<td>0.6</td>
<td>1.9</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>1.3</td>
<td>1.3</td>
<td>1.9</td>
<td>1.3</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0</td>
<td>1.3</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>0</td>
<td>1.3</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carpal tunnel syndrome</td>
<td>0</td>
<td>1.3</td>
<td>0.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3.2</td>
<td>2.6</td>
<td>3.8</td>
<td>2.0</td>
</tr>
<tr>
<td>Headache</td>
<td>10.2</td>
<td>7.8</td>
<td>8.3</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>0.6</td>
<td>0</td>
<td>1.9</td>
<td>2.0</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematuria</td>
<td>0.6</td>
<td>0</td>
<td>1.3</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>0.6</td>
<td>1.3</td>
<td>0.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Dyspnœa</td>
<td>0</td>
<td>0</td>
<td>1.3</td>
<td>0.7</td>
</tr>
<tr>
<td>Pleuritic pain</td>
<td>0</td>
<td>0</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>0</td>
<td>0</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>0.6</td>
<td>1.3</td>
<td>0.6</td>
<td>0</td>
</tr>
<tr>
<td>Purpura</td>
<td>1.3</td>
<td>1.9</td>
<td>0</td>
<td>0.7</td>
</tr>
<tr>
<td>Rash</td>
<td>1.9</td>
<td>1.9</td>
<td>0</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2.5</td>
<td>0.6</td>
<td>1.9</td>
<td>0</td>
</tr>
</tbody>
</table>
Adverse events that occurred in ≥ 1% of the MOVALIS treatment groups in two 12-week placebo controlled rheumatoid arthritis trials are presented in Table 4.

Table 4: Adverse Events (%) occurring in ≥ 1% of MOVALIS patients in two 12-week rheumatoid arthritis placebo- and active controlled trials.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>MOVALIS 7.5 mg daily</th>
<th>MOVALIS 15 mg daily</th>
<th>Diclofenac 150mg daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Patients</td>
<td>470</td>
<td>482</td>
<td>478</td>
<td>182</td>
</tr>
</tbody>
</table>

**Gastrointestinal disorders**
- Abdominal pain: 0.6, 3.1, 2.3, 4.4
- Abdominal pain upper: 0.9, 1.9, 1.0, 0
- Constipation: 0.9, 1.5, 1.7, 3.8
- Diarrhoea: 5.3, 5.2, 3.3, 6.0
- Dyspepsia: 3.6, 5.6, 3.6, 7.1
- Flatulence: 1.1, 1.2, 1.5, 5.5
- Nausea: 2.6, 3.3, 3.8, 7.7
- Vomiting: 2.3, 0.8, 1.3, 1.1

**General disorders and administration site conditions**
- Influenza like illness: 2.1, 2.3, 2.3, 5.5

**Immune system disorders**
- Hypersensitivity: 0.4, 1.2, 0.2, 0

**Infection and infestations**
- Bronchitis: 0.2, 0.6, 1.3, 0.5
- Nasopharyngitis: 0.6, 1.7, 1.9, 0
- Pharyngitis: 0.6, 0.8, 1.0, 1.1
- Rhinitis: 0.4, 0.6, 1.0, 1.1
- Sinusitis: 1.3, 1.7, 1.5, 1.6
- Upper respiratory tract infection: 2.1, 4.1, 4.0, 2.7
- Urinary tract infection: 1.3, 1.2, 1.3, 1.6

**Injury, poisoning and procedural complications**
- Fall: 0.2, 0.6, 1.0, 0.5

**Musculoskeletal and connective tissue disorders**
- Arthralgia: 1.9, 1.0, 1.7, 2.2
- Back pain: 2.3, 1.5, 1.9, 2.2
- Myalgia: 0.2, 1.0, 0.6, 0.5
- Rheumatoid arthritis: 2.3, 1.9, 1.5, 1.6

**Nervous system disorders**
- Dizziness: 3.0, 2.3, 0.6, 3.3
- Headache: 6.6, 6.6, 5.4, 9.3

**Psychiatric disorders**
- Insomnia: 0.6, 1.0, 0.6, 1.1

**Respiratory, thoracic and mediastinal disorders**
- Cough: 1.5, 0.8, 1.5, 2.2
Placebo MOVALIS 7.5 mg daily MOVALIS 15 mg daily Diclofenac 150mg daily

<table>
<thead>
<tr>
<th>Skin and subcutaneous tissue disorders</th>
<th>Placebo</th>
<th>MOVALIS 7.5 mg daily</th>
<th>MOVALIS 15 mg daily</th>
<th>Diclofenac 150mg daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pruritus</td>
<td>1.3</td>
<td>0.6</td>
<td>1.0</td>
<td>1.1</td>
</tr>
<tr>
<td>Purpura</td>
<td>0.2</td>
<td>0.2</td>
<td>1.0</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>1.7</td>
<td>1.0</td>
<td>2.3</td>
<td>3.8</td>
</tr>
</tbody>
</table>

Higher doses of MOVALIS (22.5 mg and greater) have been associated with an increased risk of serious GIT adverse events, therefore the daily dose of MOVALIS should not exceed 15 mg.

The following is a list of adverse events occurring in <1% of patients, which may be causally related to the administration of MOVALIS. The information is based on clinical trials involving patients who have been treated with daily oral doses of 7.5 or 15 mg MOVALIS tablets over a period of up to 18 months (mean duration of treatment 127 days).

**Blood and lymphatic system disorders**: blood count abnormal (including differential white cell count), leukopenia, thrombocytopenia, anaemia
Concomitant administration of a potentially myelotoxic drug, in particular methotrexate, appears to be a predisposing factor to the onset of a cytopenia.

**Cardiac disorders**: palpitations

**Ear and labyrinth disorders**: tinnitus

**Gastrointestinal disorders**: gastrointestinal perforation, occult or macroscopic gastrointestinal haemorrhage, gastroduodenal ulcer, colitis, oesophagitis, stomatitis
Gastro-intestinal haemorrhage, ulceration or perforation may potentially be fatal.

**Hepatobiliary disorders**: transitory abnormalities of liver function parameters (e.g. raised transaminases or bilirubin)

**Nervous system disorders**: somnolence

**Renal and urinary disorders**: renal function test abnormal (increased serum creatinine and/or serum urea)

**Respiratory, thoracic and mediastinal disorders**: onset of asthma attacks in individuals allergic to aspirin or other NSAIDs.

**Skin and subcutaneous tissue disorders**: urticaria, photosensitivity reaction

**Vascular disorders**: flushing

**POST-MARKET ADVERSE DRUG REACTIONS**
Additional reports of adverse events which may be causally associated to the administration of MOBIC during worldwide post-marketing experience are included below.

**General disorders and administration site conditions**: In rare cases, other drugs of this class are reported to cause meningitis.

**Eye disorders**: visual disturbance including blurred vision, conjunctivitis

**Gastrointestinal disorders**: gastritis

**Hepatobiliary disorders**: hepatitis
Immune system disorders: anaphylactic reaction, anaphylactoid reaction and other immediate hypersensitivity.

Psychiatric disorders: confusional state, disorientation, mood altered

Renal and urinary disorders: acute renal failure. The use of NSAIDs may be related to micturition disorders, including acute urinary retention.

Reproductive System and Breast Disorders: infertility female, ovulation delayed.

Skin and subcutaneous tissue disorders: toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, dermatitis bullous, erythema multiforme

OTHER ADVERSE EVENTS

Additional adverse events, reported from clinical trials or from spontaneous reports, where evidence for a causal association with meloxicam use is unclear, are the following: cardiac failure, angina, myocardial infarction, arrhythmia, vasculitis, agranulocytosis, interstitial nephritis, convulsion, liver failure.

DOSAGE AND ADMINISTRATION

The recommended dose of MOVALIS is 7.5 mg once daily, to be swallowed with fluid, in conjunction with food. Depending on the adequacy of response, the severity of the arthritic condition and the patient’s concomitant diseases, the dose may be increased to 15 mg/day. Patients should generally be maintained on the lowest dose consistent with achieving a satisfactory therapeutic response.

The maximum recommended daily dose of MOVALIS is 15 mg. A dose of 15 mg/day should not be exceeded. As a dose for children has not been established, use should be restricted to adults (see PRECAUTIONS – Paediatric Use).

The dose of MOVALIS in patients with end-stage renal failure on haemodialysis should not exceed 7.5 mg/day (see PHARMACOLOGY – Renal Impairment). No dose reduction is required in patients with mild or moderate renal impairment (i.e., in patients with a creatinine clearance of greater than 20 mL/min) nor in patients with mild to moderate hepatic impairment. In non-dialysed patients with severe renal impairment MOBIC is contraindicated (see CONTRAINDICATIONS).

In patients with an increased risk of adverse reactions, e.g. a history of gastrointestinal disease or risks for cardiovascular disease, the treatment should be started at 7.5 mg/day and increased to 15 mg/day only if clinically justified.

MOVALIS should be used at the lowest dose and for the shortest duration consistent with effective treatment.

OVERDOSAGE

In case of poisoning or overdose, advice should be sought from a Poisons Information Centre (telephone 13 11 26).

Patients should be managed with symptomatic and supportive care following an NSAID overdose. In cases of acute overdose, activated charcoal is recommended. Administration of activated
charcoal is recommended for patients who present 1-2 hours after overdose. For substantial overdose or severely symptomatic patients, activated charcoal may be administered repeatedly.

It has been shown in a clinical trial that cholestyramine accelerates the elimination of meloxicam.

The typical signs and symptoms of NSAID overdose include nausea, vomiting, headache, drowsiness, blurred vision and dizziness. Rare cases of seizures, hypotension, apnoea, coma and renal failure have been reported with severe NSAID overdose.

PRESENTATION AND STORAGE CONDITIONS

Tablets 7.5 mg: Pastel-yellow, round tablets, marked 59D on one side with break bar, and no markings on the other. Each tablet contains meloxicam 7.5 mg. Blister packs: 10*, 20*, 30, 60*, 100* tablets.

Tablets 15 mg: Pastel-yellow, round tablets, marked 77C on one side with break bar, and no markings on the other. Each tablet contains meloxicam 15 mg. Blister packs: 10*, 20*, 30, 60*, 100* tablets.

*not currently distributed in Australia

TABLETS (blister packs): Store below 25°C

Protect from direct sunlight.

NAME AND ADDRESS OF THE SPONSOR

Aspen Pharma Pty Ltd
34-36 Chandos Street
St Leonards NSW 2065
Australia

POISON SCHEDULE OF THE MEDICINE

S4 – Prescription Only Medicine

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (THE ARTG)

12 March 2004

DATE OF MOST RECENT AMENDMENT

24 December 2014